论文部分内容阅读
目的观察替米沙坦对高血压患者纤溶功能的影响。方法 入选初诊为原发性高血压患者116例为研究对象,同期年龄和性别相匹配的健康体检者113人为对照组。高血压患者给予替米沙坦40~80mg/d,治疗12周。观察高血压患者治疗前后血浆组织型纤溶酶原激活物(t-PA)和内皮细胞型纤溶酶原激活物抑制剂(PAI-1)水平的变化。结果 治疗前高血压患者血浆t-PA水平明显低于对照组,PAI-1水平明显高于对照组(均P<0·01)。替米沙坦治疗12周后,高血压患者的血压显著下降,血浆t-PA水平升高,PAI-1水平下降,t-PA/PAI-1升高(均P<0·01)。结论 替米沙坦可改善高血压患者的纤溶功能。
Objective To observe the effect of telmisartan on fibrinolytic function in patients with essential hypertension. Methods One hundred and sixty-six patients with primary hypertension were enrolled in this study. One hundred and seventy healthy subjects whose age and gender matched over the same period were selected as the control group. Patients with hypertension were given telmisartan 40 ~ 80mg / d for 12 weeks. To observe the changes of plasma tissue-type plasminogen activator (t-PA) and endothelial cell-type plasminogen activator inhibitor (PAI-1) in patients with hypertension before and after treatment. Results The level of plasma t-PA in patients with hypertension before treatment was significantly lower than that in the control group, and the PAI-1 level was significantly higher than that in the control group (all P <0.01). After 12 weeks of treatment with telmisartan, the blood pressure of patients with essential hypertension decreased significantly, the level of plasma t-PA increased, the level of PAI-1 decreased and the level of t-PA / PAI-1 increased (all P <0.01). Conclusion Telmisartan can improve fibrinolysis in hypertensive patients.